The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 14, Pages 3433
Publisher
MDPI AG
Online
2021-07-08
DOI
10.3390/cancers13143433
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Thrombopoietin Promotes Angiogenesis and Disease Progression in Patients with Multiple Myeloma
- (2021) Aurelia Lamanuzzi et al. AMERICAN JOURNAL OF PATHOLOGY
- Subgroup-Independent Mapping of Renal Cell Carcinoma—Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries
- (2021) André Marquardt et al. Frontiers in Oncology
- Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment
- (2021) Darya Javadrashid et al. Biomedicines
- Immune system and bone microenvironment: rationale for targeted cancer therapies
- (2020) Gnoni Antonio et al. Oncotarget
- miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro
- (2020) Markus Krebs et al. Journal of Clinical Medicine
- Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
- (2020) Paola Ciciola et al. Journal of Clinical Medicine
- HB-EGF–EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma
- (2020) Luigia Rao et al. Cancers
- Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
- (2020) Yolla Haibe et al. Frontiers in Oncology
- Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression.
- (2020) Antonio G. Solimando et al. HAEMATOLOGICA
- The Epigenetic Profile of Tumor Endothelial Cells. Effects of Combined Therapy with Antiangiogenic and Epigenetic Drugs on Cancer Progression
- (2020) Oskar Ciesielski et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
- (2020) Marco Russano et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
- (2020) Antonella Argentiero et al. Journal of Clinical Medicine
- A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche
- (2020) Antonio Giovanni Solimando et al. Journal of Oncology
- Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
- (2020) Emilie Alard et al. Cancers
- New Insights into Diffuse Large B-Cell Lymphoma Pathobiology
- (2020) Antonio Giovanni Solimando et al. Cancers
- Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
- (2020) Christopher Montemagno et al. Frontiers in Cell and Developmental Biology
- Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
- (2020) Antonio Giovanni Solimando et al. Cancers
- CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer
- (2019) Letizia Porcelli et al. Cancers
- δ-catenin promotes bevacizumab-induced glioma invasion
- (2019) Toshihiko Shimizu et al. MOLECULAR CANCER THERAPEUTICS
- Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse
- (2019) Octavio D. Arevalo et al. Frontiers in Neurology
- Cathepsin L-induced galectin-1 may act as a proangiogenic factor in the metastasis of high-grade serous carcinoma
- (2019) Md Zahidul I. Pranjol et al. Journal of Translational Medicine
- Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study
- (2019) Antonella Argentiero et al. Cancers
- Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview
- (2019) Antonella Argentiero et al. Cancers
- Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214
- (2019) Bernard Escudier et al. EUROPEAN UROLOGY
- Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs
- (2019) Patrizia Leone et al. Journal of Clinical Medicine
- Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression
- (2019) María Romina Girotti et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma
- (2018) Vanessa Desantis et al. ANNALS OF HEMATOLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk
- (2018) Carlos A. Orozco et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
- (2018) Aurelia Lamanuzzi et al. Oncotarget
- Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study
- (2018) Luigia Rao et al. Oncotarget
- Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients
- (2018) Patrizia Leone et al. OncoImmunology
- Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
- (2017) David Miles et al. EUROPEAN JOURNAL OF CANCER
- First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial
- (2017) Norikazu Masuda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism
- (2017) Tabea Wiedmer et al. MOLECULAR CANCER THERAPEUTICS
- The small subunit of Hemilipin2, a new heterodimeric phospholipase A2 from Hemiscorpius lepturus scorpion venom, mediates the antiangiogenic effect of the whole protein
- (2017) Imen Jridi et al. TOXICON
- Galectin 3 as a guardian of the tumor microenvironment
- (2016) Peter P. Ruvolo BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
- (2016) Charles S Fuchs et al. BRITISH JOURNAL OF CANCER
- VEGF/NRP-1 axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin
- (2016) Minna Luo et al. CANCER LETTERS
- BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
- (2016) A. B. Benson et al. CLINICAL CANCER RESEARCH
- Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
- (2016) Etienne Becht et al. CLINICAL CANCER RESEARCH
- Role of the tumor stroma in resistance to anti-angiogenic therapy
- (2016) Elisabeth J.M. Huijbers et al. DRUG RESISTANCE UPDATES
- Antiangiogenic therapy in oncology: current status and future directions
- (2016) Gordon C Jayson et al. LANCET
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- Hypoxic control of metastasis
- (2016) E. B. Rankin et al. SCIENCE
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux
- (2015) Sandy Giuliano et al. Autophagy
- Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting
- (2015) Diether Lambrechts et al. BRITISH JOURNAL OF CANCER
- Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
- (2015) A J Weickhardt et al. BRITISH JOURNAL OF CANCER
- Neuropilin-2 mediates lymphangiogenesis of colorectal carcinoma via a VEGFC/VEGFR3 independent signaling
- (2015) Juan-Juan Ou et al. CANCER LETTERS
- Computational systems biology approaches to anti-angiogenic cancer therapeutics
- (2015) Stacey D. Finley et al. DRUG DISCOVERY TODAY
- Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial
- (2015) Thomas Sandmann et al. JOURNAL OF CLINICAL ONCOLOGY
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Cathepsin L targeting in cancer treatment
- (2015) Dhivya R. Sudhan et al. PHARMACOLOGY & THERAPEUTICS
- Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
- (2015) Rebecca S. Heist et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
- (2015) Sara M. Tolaney et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors
- (2014) Diego O. Croci et al. CELL
- Blocking Lipid Synthesis Overcomes Tumor Regrowth and Metastasis after Antiangiogenic Therapy Withdrawal
- (2014) Nor Eddine Sounni et al. Cell Metabolism
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis
- (2013) Benoit Beuselinck et al. ACTA ONCOLOGICA
- Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology
- (2013) Gregg L. Semenza Annual Review of Pathology-Mechanisms of Disease
- Mechanisms of resistance to anti-angiogenesis therapies
- (2013) Sandy Giuliano et al. BIOCHIMIE
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- (2013) D W Miles et al. BRITISH JOURNAL OF CANCER
- Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
- (2013) B Beuselinck et al. BRITISH JOURNAL OF CANCER
- A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
- (2013) Shahneen K. Sandhu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
- (2013) A. Jahangiri et al. CLINICAL CANCER RESEARCH
- Markers of Response for the Antiangiogenic Agent Bevacizumab
- (2013) Diether Lambrechts et al. JOURNAL OF CLINICAL ONCOLOGY
- AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
- (2013) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
- (2013) T. T. Batchelor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Coronary Microvascular Pericytes Are the Cellular Target of Sunitinib Malate-Induced Cardiotoxicity
- (2013) V. Chintalgattu et al. Science Translational Medicine
- Endothelial Cell Heterogeneity
- (2013) W. C. Aird Cold Spring Harbor Perspectives in Medicine
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
- (2013) Laetitia Marisa et al. PLOS MEDICINE
- Biomarkers for antitumor activity of bevacizumab in gastric cancer models
- (2012) Yoriko Yamashita-Kashima et al. BMC CANCER
- Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
- (2012) Astrid A.M. Van der Veldt et al. CANCER CELL
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
- (2012) Farbod Shojaei et al. CANCER LETTERS
- Targeting Galectin-1 Overcomes Breast Cancer-Associated Immunosuppression and Prevents Metastatic Disease
- (2012) T. Dalotto-Moreno et al. CANCER RESEARCH
- A preclinical and clinical review of aflibercept for the management of cancer
- (2012) Andrew Gaya et al. CANCER TREATMENT REVIEWS
- Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer
- (2012) Pedro Villarejo-Campos et al. Clinical & Translational Oncology
- Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications
- (2012) D. A. Kirschmann et al. CLINICAL CANCER RESEARCH
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis
- (2012) Yuan Xu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer
- (2012) Stefan Bentink et al. PLoS One
- The VHL/HIF axis in clear cell renal carcinoma
- (2012) Chuan Shen et al. SEMINARS IN CANCER BIOLOGY
- Endothelial precursor cells promote angiogenesis in hepatocellular carcinoma
- (2012) Xi-Tai Sun WORLD JOURNAL OF GASTROENTEROLOGY
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- Imaging Key Biomarkers of Tumor Angiogenesis
- (2012) Marina V. Backer et al. Theranostics
- Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
- (2012) Salem Chouaib et al. Frontiers in Immunology
- Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
- (2011) Eric Tartour et al. CANCER AND METASTASIS REVIEWS
- Intussusceptive microvascular growth in tumors
- (2011) Domenico Ribatti et al. CANCER LETTERS
- Novel angiogenesis inhibitors: Addressing the issue of redundancy in the angiogenic signaling pathway
- (2011) Domenico Ribatti CANCER TREATMENT REVIEWS
- Normalization of the Vasculature for Treatment of Cancer and Other Diseases
- (2011) Shom Goel et al. PHYSIOLOGICAL REVIEWS
- Bevacizumab improves the delivery and efficacy of paclitaxel
- (2010) Mieko Yanagisawa et al. ANTI-CANCER DRUGS
- Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer
- (2010) Shioto Suzuki et al. BMC CANCER
- Hypoxia, inflammation, and the tumor microenvironment in metastatic disease
- (2010) Elizabeth C. Finger et al. CANCER AND METASTASIS REVIEWS
- HIF-1α and HIF-2α correlate with migration and invasion in gastric cancer
- (2010) Yanxia Wang et al. CANCER BIOLOGY & THERAPY
- Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
- (2010) H. Hashizume et al. CANCER RESEARCH
- Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer
- (2010) D. G. Duda et al. ONCOLOGIST
- Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6
- (2010) YOSHIKO AOYAGI et al. Oncology Letters
- Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
- (2009) Sonja Loges et al. CANCER CELL
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- (2009) Jorg Hartmann et al. CURRENT DRUG METABOLISM
- Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
- (2009) Annamaria Rapisarda et al. DRUG RESISTANCE UPDATES
- Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
- (2009) Christopher G. Willett et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
- (2008) R. M. Zuniga et al. JOURNAL OF NEURO-ONCOLOGY
- Multimodality Molecular Imaging of Tumor Angiogenesis
- (2008) W. Cai et al. JOURNAL OF NUCLEAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation